Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
Kausik Kumar Ray, Douglas Kling, Philip Scheltens, Jeffrey L. Cummings et al.
Citations
7 citations
Journal
The Journal of Prevention of Alzheimer s Disease
Topics
Computational Drug Discovery Methods
Field-Weighted Citation Impact (FWCI)
10.53
article
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
Kausik Kumar Ray, Douglas Kling, Philip Scheltens, Jeffrey L. Cummings, Danielle Curcio, Michael Szarek, John J.P. Kastelein, Marc Ditmarsch, Everard G.B. Vijverberg, Andrew Hsieh, Michael H Davidson, Stephen J Nicholls
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
The Journal of Prevention of Alzheimer s DiseaseVol. 13(1)
Institutions
University of Nevada, Las Vegas (US), Korea Pharma (South Korea) (KR), Mount Sinai Hospital (US), Amsterdam Neuroscience (NL), Imperial College London (GB), Monash University (AU), University of Amsterdam (NL)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease — Kausik Kumar Ray, Douglas Kling, et al. · The Journal of Prevention of Alzheimer s Disease (2025) | TGRS Research Map | TGRS